Alma Fulurija

Alma Fulurija is an immunologist and holds a PhD from the University of Western Australia. She has more than 15 years of experience in the biotech and pharma sectors working at the interface of academia and industry. Prior to joining ASAVI, Alma has led research and development projects both in Australia and Switzerland, most recently as Head of Research & Development at Ondek Pty Ltd., a Perth-based biotech company developing bacterial-based immunotherapies for the prevention of allergic diseases. She also held positions at Cytos Biotechnology AG in Zurich and completed postdoctoral training at the WHO Centre for Neonatal Immunology and Vaccinology in Geneva. Alma is an Adjunct Associate Professor at the University of Western Australia, where she is a researcher and lecturer in immunology and supervises post-doctoral fellows and higher degree students. Her research involves understanding vaccine development for infectious diseases such as Streptococcus pyogenes, Helicobacter pylori, otitis media and other infections.

Alma has a strong interest in translating evidence-based research into clinical outcomes and has a deep understanding of immunology, preclinical and early clinical development of vaccines and immunotherapies.